Healthy Heart

**Volume-4 | Issue-38 | January 5, 2013**

***From the desk of Editor:***

Approximately 50% to 60% of patients with congestive heart failure have some degree of mitral regurgitation (MR), and in 30% of these, the MR is moderate or severe. The majority of these individuals have a structurally normal mitral valve (MV), but the valve is incompetent because of left ventricular remodeling that has disturbed

the relationship between the subvalvular apparatus and the MV leaflets. This type of MR is referred to as functional MR. Functional MR in the subgroup of patients in which the underlying ventricular remodeling is due to a myocardial infarction (MI), is referred to as ischemic MR. The presence of MR after an MI is associated with a worse prognosis. In those with 3 + to 4+ MR, the 5 – year survival is approximately 50%, even with surgical intervention. Coronary revascularization does little to improve the severity of the regurgitation. Although MR can be resolved acutely with mitral valve repair, there is a high rate of recurrence. Newer surgical techniques are focusing on the subvalvular apparatus in an attempt to achieve better results. The data with these techniques are limited, and the long – term results are not known. The constraint devices, along with the percutaneous approaches, show promise, but more data are needed before their widespread use. **– Dr. Dhiren Shah**

**Surgical Options of Ischemic Mitral Regurgitation**

**Definition, Classification and Pathophysiology of Chronic Ischemic Mitral Regurgitation**

Ischemic MR is defined as MR complicating the manifestations of coronary artery disease in the absence of primary leaflet, or chordal pathology. Any disruption of the proper function of the mitral annulus, the valve leaflets, the chordate tendineae, the papillary muscles, or the supporting left ventricular walls may lead to MR.

The cause of MR in ischemic MR is due to (1) mitral annular dilatation, and/or (2) papillary muscle displacement. This process causes (1) leaflet malcoaptation, which is the failure of the leaflets to meet, and (2) malapposition, which is the failure of the leaflets to close at the same plane . Although mitral annular dilatation has been described as a cause of MR, it has been shown that isolated annular dilatation, per se, does not cause significant regurgitation. In only 5% of the cases of ischemic MR does annular dilatation play a significant role. This means that the predominant cause of ischemic MR is the apical and lateral displacement of the papillary muscles, leading to tethering of the MV leaflets, with subsequent decreased coptation. This tethering of the leaflets is more commonly seen after a posteroinferior then an anterolateral wall MI. Therefore, it is more common for the posteromedial papillary muscle to be the culprit associated with ischemic MR.



**Coronary Artery Revascularization**

Since the underlying cause of ischemic MR is coronary artery disease, it would seen intuitive that coronary artery revascularization would ameliorate the severity of the MR. However, the data shows that in most patients coronary artery revascularization does not correct the MR. A study of 136 patients with ischemic MR who underwent isolated coronary artery bypass graft surgery (CABG) showed on postoperative transthoracic echocardiogram that 40% of patient were left with 3 to 4 + MR, and 51% were left with 2+ MR. Only 9% of patients had significant improvement, with no more then trace (0 to 1+) MR. Another report of 92 patients with 3+ to 4+ ischemic MR undergoing isolated CABG showed that

in postoperative echocardiographic follow – up, nearly half the patients still had 3+ to 4 + MR.

**CABG versus CABG And MV Repair**

To date, no randomized trial has been conducted to evaluate the efficacy of MV repair when performed at the time of CABG. The published data have all been retrospective analyses. Wu et al evaluated 682 patients with moderate to severe MR and ejection fraction < 30% who underwent CABG ; 419 patients underwent CABG alone, and 126 underwent CABG with MV repair . When the CABG MV repair group was compared with the CABG group, there was no demonstrable mortality benefit conferred by the MV repair. Another study from the Cleveland Clinic evaluated 390 patients with 3+/ 4 + MR, with varying degrees of left ventricular systolic dysfunction . Of these, 290 patients underwent CABG with MV repair and were compared with 100 patients who underwent CABG alone. Their conclusions were that the addition of MV annuloplasty to CABG did not improve long – term functional status or survival. Similar studies have come to the same conclusions.

**Mitral Valve Replacements**

Although no randomized trial has been performed comparing the benefits of MV replacement versus MV repair, it appears that MV repair has a lower operative mortality and a better long – term survival when compared with MV replacement. However, MV replacement is still a reasonable option for patients with acute MR, and for those with chronic ischemic MR and multiple comorbidities, complex regurgitant jets ( noncentral jet or more then one jet ), or severe tethering of both MV leaflets. When considering which type of valve to implant, it is important to take into account that the majority of patients do not survive much longer then 5 years. A bioprosthetic valve in the mitral position starts to deteriorate approximately 6 years postimplant. As a result, some surgeons recommend the use of a bioprosthetic valve over a mechanical one, irrespective of the patient's age, to avoid chronic anticoagulation. Also, chordal preservation is less technically demanding, and there are fewer potential postoperative valve-related complications if a bioprosthetic valve is used.

To evaluate the safety and efficacy of MV repair and MV replacement for patients with severe ischemic MR, a multicenter randomized trial titled “ Evaluation of Outcomes Following Mitral Valve Repair/ Replacement in Severe Chronic Ischemic Mitral Regurgitation is now taking place.



**Figure-2 : Restricted leaflet motion. It is**

**noticed in the cross sectional view of the**

**mitral valve that segments P3/P2 do not coapt**

**due to restricted motion of the leaflet. Type**

**IIIb dysfunction of Carpentier's classification.**

Patients will be randomized to MV repair with annuloplasty and a subvalvular procedure for severe

tethering, or to MV replacement with complete preservation of the subvalvular apparatus. The primary end point of the study is the degree of left ventricular remodeling at 12 months .

**Mitral Valve Repair**

The most common type of surgery performed for ischemic MR is an undersized mitral annuloplasty. In this technique, a small (size 24 to 26 mm) mitral annuloplasty ring is used which causes a reduction in the anteroposterior (septolateral) diameter of the MV increasing the surface of coaptation. The procedure is fairly easy to perform and reproducible. Over the past few years, many different types of prosthetic rings have been developed, some are flexible, others rigid, some are complete, others incomplete. However, there are no definite data that show that one ring is superior to another.

****

**A B C**

**Figure-3 : Anterior leaflet augmentation. A, the mitral valve as viewed from the surgeon's perspective with sutures in the posterior annulus. An incision is made in the anterior leaflet from commissure to commissure, with a resultant elliptical defect. B, Anterior leaflet augmented with bovine pericardium. C, Completed repair with partial, flexible annuloplasty ring.**

**Surgical Ventricular Restoration with Papillary Muscle Imbrication**

The term “Surgical Ventricular Restoration” includes operative methods that reduce left ventricular volume and restore the ventricular elliptical shape. Its use is limited to anterior wall MIs. In this technique, the anteroseptal, apical, and anterolateral left ventricular scarred segments are excluded from the rest of left ventricle with an intracardiac patch or by direct closure. By altering the shape of the left ventricle and reducing wall stress, this procedure can reduce papillary muscle displacement and subsequent MR.

****

**Figure : Infarct Plication. A, schematic representation of the akinetic inferobasal segment with tethering of the posterior leaflet. The sutures are shown before tightening. B, Plication of the dyskinetic segment with relocation of the posterior papillary muscle. LA indicates Left atrium; LV, left ventricle; Ao, aorta; IMR, ischemic mitral regurgitation; PPM, posterior papillary muscle.**

**External Compression Devices**

An innovative strategy to remodeling has been the development of constraint devices. These devices are intended to improve left ventricular function by reducing wall stress, and provide passive diastolic support. The Acorn Corcap cardiac support device is a biocompatible mesh – like jacket that slips around the heart during surgery. It was evaluated in the ACORN trial, which was an unblinded trial that randomized 300 patients to 2 treatment arms depending on a need for MV surgery or only medical treatment, with or without use of the support device. In the subgroup of 193 patients who were enrolled in the MV repair/ replacement stratum, 102 patients were randomized to the MV surgery alone group (control), and 91 were randomized to the MV surgery with implantation of the support device. At 23 months median follow – up, the addition of the support device led to greater decreases in left ventricular volumes, a more elliptical left ventricle shape, a trend for reduction in major cardiac procedures, and improvement in quality of life compared with MV surgery alone .

**Percutaneous Procedures**

The percutaneous approach for the treatment of MR is in its early stages of development. One approach to reduce in the coronary sinus. The CARILLON Mitral Annuloplasty Device European Union Study (AMADEUS) study showed that at 6 months, the device reduced MR by 23% and improved quality of life and exercise tolerance.

Another technique uses a trans – septal approach to perform an edge – to – edge mitral valve repair by placing a clip in the center of the mitral orifice. This was evaluated in the Endovascular Valve Edge-to-Edge Repair studies ( EVEREST I and II ). A total of 107 patients with 3+ to 4+ MR were treated. Acute procedural success was achieved in 79 of 107 ( 74% ) patients, and 51 (64%) were discharged with MR of < 1+. Thirty – two patients, (30%) had mitral valve surgery during the 3.2 years after the clip procedure. A total of 50 of 76 (66%) successfully – treated patients were free from death, mitral valve surgery, or MR >2+ at 12 months. Kaplan – meier freedom from death was 95.9%, 94.0%, and 90.1% and Kaplan – Meier freedom from surgery was 88.5%, 83.2%, and76.3% at 1, 2, and 3 years, respectively. The 23 patients with functional MR had similar acute results and durability.

**Recommendations / Our Experience**

The American College of Cardiology / American Heart Association state in their latest valvular heart disease guidelines that “ The best operation for ischemic MR is controversial, but MV repair with an annuloplasty ring is the procedure of choice in most instances.” At our institution, MV repair for

ischemic MR usually involves implanting a complete rigid saddle – shaped ring and dog bone shaped (GeoForm ring), sized to the intertrigonal space and anterior leaflet. In patients who do not need coronary revascularization, we perform all the MV repairs via a minimally invasive approach, regardless of the left ventricular function.

CIMS Cardiac Surgery

One of the most reputed cardiac surgical care team of India

* Congenital heart surgery
* Minimal Invasive Cardiac Surgery (MICS)
* Mitral valve repair
* Single, double and multiple valve replacement / repair
* Aortic root replacement
* Off Pump CABG on beating heart
* CABG with SVR (Surgical Ventricular Restoration) for CAD, LV dysfunction, CHF
* PDA, ASD, VSD, TOF etc
* Combined carotid and by pass procedure